Nothing Special   »   [go: up one dir, main page]

HK1029928A1 - Pharmaceutical compositions of peptides having lowsolubility in physiological medium. - Google Patents

Pharmaceutical compositions of peptides having lowsolubility in physiological medium.

Info

Publication number
HK1029928A1
HK1029928A1 HK01100764A HK01100764A HK1029928A1 HK 1029928 A1 HK1029928 A1 HK 1029928A1 HK 01100764 A HK01100764 A HK 01100764A HK 01100764 A HK01100764 A HK 01100764A HK 1029928 A1 HK1029928 A1 HK 1029928A1
Authority
HK
Hong Kong
Prior art keywords
lowsolubility
peptides
pharmaceutical compositions
physiological medium
physiological
Prior art date
Application number
HK01100764A
Other languages
English (en)
Inventor
Peter Richardson
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP97108593A external-priority patent/EP0880968A1/en
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of HK1029928A1 publication Critical patent/HK1029928A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK01100764A 1997-05-28 2001-02-02 Pharmaceutical compositions of peptides having lowsolubility in physiological medium. HK1029928A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97108593A EP0880968A1 (en) 1997-05-28 1997-05-28 Pharmaceutical compositions of peptides having low solubility in physiological medium
EP97121246A EP0880969A1 (en) 1997-05-28 1997-12-03 Pharmaceutical compositions of peptides having low solubility in physiological medium
PCT/EP1998/003079 WO1998053844A1 (en) 1997-05-28 1998-05-26 Pharmaceutical compostions of peptides having low solubility in physiological medium

Publications (1)

Publication Number Publication Date
HK1029928A1 true HK1029928A1 (en) 2001-04-20

Family

ID=26145485

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01100764A HK1029928A1 (en) 1997-05-28 2001-02-02 Pharmaceutical compositions of peptides having lowsolubility in physiological medium.

Country Status (27)

Country Link
US (1) US6331520B1 (xx)
EP (2) EP0880969A1 (xx)
JP (1) JP2002502384A (xx)
KR (1) KR100552546B1 (xx)
CN (1) CN1159062C (xx)
AR (1) AR012868A1 (xx)
AT (1) ATE252909T1 (xx)
AU (1) AU743152B2 (xx)
BG (1) BG64668B1 (xx)
BR (1) BR9809708A (xx)
CA (1) CA2291765A1 (xx)
CZ (1) CZ298825B6 (xx)
DE (1) DE69819322T2 (xx)
DK (1) DK0984788T3 (xx)
EA (1) EA002227B1 (xx)
EE (1) EE04001B1 (xx)
ES (1) ES2210772T3 (xx)
HK (1) HK1029928A1 (xx)
IL (2) IL133176A0 (xx)
NO (1) NO323697B1 (xx)
NZ (1) NZ500777A (xx)
PL (1) PL192647B1 (xx)
PT (1) PT984788E (xx)
SI (1) SI0984788T1 (xx)
SK (1) SK284640B6 (xx)
TR (1) TR199902865T2 (xx)
WO (1) WO1998053844A1 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343186B2 (en) 2004-04-06 2013-01-01 Arthrex, Inc. Fully threaded suture anchor with transverse anchor pin
EP1064934A1 (en) 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
CA2380423A1 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
US20040229334A1 (en) * 2003-05-15 2004-11-18 Mendoza Christine B. Process for manufacture of nematode-extracted anticoagulant protein (NAP)
CA2680329A1 (en) * 2007-04-04 2008-10-16 Theratechnologies Inc. Pharmaceutical formulations of ghrh molecules
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
US9023826B2 (en) 2012-10-12 2015-05-05 L'oreal S.A. Compositions containing adenosine and the hydrotropes caffeine and nicotinamide for cosmetic use
WO2014059228A1 (en) * 2012-10-12 2014-04-17 L'oreal Cosmetic compositions containing at least one hydrotrope and at least one active compound
US9018177B2 (en) 2012-10-12 2015-04-28 L'oreal S.A. Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C
US9072919B2 (en) 2012-10-12 2015-07-07 L'oreal S.A. Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid
US9107853B2 (en) 2012-10-12 2015-08-18 L'oreal S.A. Compositions containing phenolic compounds and hydrotropes for cosmetic use
US9669242B2 (en) 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
BR112018016774A2 (pt) 2016-02-16 2018-12-26 Strongbridge Ireland Limited veldoreotídeo com fraca solubilidade em condições fisiológicas para o uso no tratamento da acromegalia, câncer em acromegalia, tumores que expressam sst-r5, diabetes tipo 2, hiperglicemia e tumores relacionados a hormônio
TW202031283A (zh) 2018-09-20 2020-09-01 馬克 C 曼寧 穩定卡貝縮宮素鼻內製劑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
ES2072596T3 (es) * 1989-12-21 1995-07-16 Novo Nordisk As Preparaciones de insulina que contienen acido nicotinico o nicotinamida.
CA2070061C (en) * 1991-06-07 2004-02-10 Shigeyuki Takama Physiologically active polypeptide-containing pharmaceutical composition
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
ATE197126T1 (de) * 1991-08-26 2000-11-15 Abbott Lab Verbindungen und methoden zur sublingualen oder buccalen verabreichung von therapeutischen agentien
US5446025A (en) * 1992-06-12 1995-08-29 Abbott Laboratories Formulations and method of the percutaneous administration of leuprolide
JP2944419B2 (ja) * 1993-05-10 1999-09-06 ノバルティス アクチエンゲゼルシャフト 持続性遊離組成物中の薬理学的活性成分の安定
TW280770B (xx) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
AU3562195A (en) * 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제

Also Published As

Publication number Publication date
PL192647B1 (pl) 2006-11-30
IL133176A0 (en) 2001-03-19
BG103884A (en) 2000-07-31
JP2002502384A (ja) 2002-01-22
EA002227B1 (ru) 2002-02-28
CN1159062C (zh) 2004-07-28
US6331520B1 (en) 2001-12-18
NO995763D0 (no) 1999-11-24
WO1998053844A1 (en) 1998-12-03
EE04001B1 (et) 2003-04-15
ATE252909T1 (de) 2003-11-15
DE69819322T2 (de) 2004-07-29
DE69819322D1 (de) 2003-12-04
IL133176A (en) 2006-08-01
DK0984788T3 (da) 2004-03-08
AU8106298A (en) 1998-12-30
SK159799A3 (en) 2000-07-11
CZ423199A3 (cs) 2000-05-17
NZ500777A (en) 2001-09-28
PT984788E (pt) 2004-01-30
EP0880969A1 (en) 1998-12-02
SK284640B6 (sk) 2005-08-04
CA2291765A1 (en) 1998-12-03
EE9900545A (et) 2000-06-15
KR20010012253A (ko) 2001-02-15
BG64668B1 (bg) 2005-11-30
EP0984788B1 (en) 2003-10-29
TR199902865T2 (xx) 2000-05-22
CZ298825B6 (cs) 2008-02-20
AR012868A1 (es) 2000-11-22
EP0984788A1 (en) 2000-03-15
KR100552546B1 (ko) 2006-02-14
EA199901089A1 (ru) 2000-06-26
PL336982A1 (en) 2000-07-31
SI0984788T1 (en) 2004-02-29
NO995763L (no) 1999-11-24
NO323697B1 (no) 2007-06-25
ES2210772T3 (es) 2004-07-01
CN1263469A (zh) 2000-08-16
BR9809708A (pt) 2000-07-11
AU743152B2 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
EP0950665A4 (en) PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM
HUP0003761A3 (en) Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
HUP9701554D0 (en) Pharmaceutical composition containing plazma proteins
IL136044A0 (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
IL131293A (en) Pyrazine compounds, their preparation and pharmaceutical compositions comprising them
HUP0004398A3 (en) Alpha-aryl-n-alkylnitrones and pharmaceutical compositions containing the same
HUP0100149A3 (en) Antipicornaviral peptide derivatives pharmaceutical compositions comprising thereof and their use
GB9706089D0 (en) Pharmaceutical composition
HUP0001309A3 (en) 1-phenyl-4-benzylpiperazines and pharmaceutical compositions containing them
HUP0000762A3 (en) 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines, and pharmaceutical compositions containing them
HK1029928A1 (en) Pharmaceutical compositions of peptides having lowsolubility in physiological medium.
HUP9800147A3 (en) Isoxasol-and crotonoil-amide derivatives and pharmaceutical and diagnostical compositions containing them
ZA983849B (en) Pharmaceutical compositions of tizoxanide and nitazoxanide.
HUP9802132A3 (en) Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them
HUP0101701A3 (en) Substituted betha-alanines and pharmaceutical compositions comprising them
ZA9811655B (en) Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same
GB9717444D0 (en) Pharmaceutical composition
IL125908A0 (en) Peptides and pharmaceutical compositions comprising same
GB9717428D0 (en) Pharmaceutical composition
HK1025907A1 (en) Pharmaceutical compositions of tizoxanide and nitazoxanide.
IL131266A0 (en) Peptides and pharmaceutical compositions comprising same
GB9700855D0 (en) Pharmaceutical composition
HUP0002118A3 (en) Pharmaceutical compositions of peptides having low solubility in physiological medium
GB9726781D0 (en) Pharmaceutical composition
ZA984469B (en) Pharmaceutical compositions of peptides having low solubility of physiological medium

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080526